Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.Characteristics and survival of patients treated with afatinib after resistance to erlotinib or gefitinib in...

Full description

Bibliographic Details
Main Authors:	A J van der Wekken, J L Kuiper, A Saber, M M Terpstra, J Wei, T J N Hiltermann, E Thunnissen, D A M Heideman, W Timens, E Schuuring, K Kok, E F Smit, A van den Berg, H J M Groen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5576694?pdf=render

Similar Items

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
by: Arenda D. Meedendorp, et al.
Published: (2018-05-01)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
by: Yen-Ju Chen, et al.
Published: (2021-01-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
by: Ribeiro Gomes J, et al.
Published: (2015-05-01)

EGFR and SOX2 crosstalk determines EGFR-TKI sensitivity and tumor progression
by: LEE, AN-CHUN, et al.
Published: (2018)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
by: Antonio Passaro, et al.
Published: (2021-07-01)

Treatment Choice After EGFR-TKI Resistance
by: Junling LI
Published: (2013-10-01)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
by: Seo Yun Kim, M.D., et al.
Published: (2019-01-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
by: Fu-Tsai Chung, et al.
Published: (2015-01-01)

Characterization of the Small Compounds -T315 on EGFR Degradation in EGFR-TKI Resistant Lung Adenocarcinoma
by: Kuo-Yen Huang, et al.
Published: (2015)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

Afatinib: new treatment options for lung cancer with activating EGFR mutations
by: M. V. Stepanchenko, et al.
Published: (2015-12-01)

A Nationwide Study on the Impact of Routine Testing for <i>EGFR</i> Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on <i>EGFR</i> Mutation Subclasses
by: Bart Koopman, et al.
Published: (2021-07-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
by: Jeng-Shiuan Tsai, et al.
Published: (2021-09-01)

Effects of afatinib through other target proteins than EGFR
by: Jia-Feng Mao, et al.
Published: (2018)

Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI
by: Yi SHAO, et al.
Published: (2020-05-01)

EGFR-TKI ADR Management Chinese Expert Consensus
by: Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
Published: (2019-02-01)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance
by: Zhentao Liu, et al.
Published: (2018-08-01)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
by: Wu JX, et al.
Published: (2018-10-01)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
by: Michael E Goldberg, et al.
Published: (2018-01-01)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
by: Tohru Ohmori, et al.
Published: (2021-01-01)

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01)

The investigation of neuroprotective effect of EGFR-TKI: in vitro and in vivo studies
by: Wei-Zhong Zhao, et al.
Published: (2017)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
by: Jiacong Wei, et al.
Published: (2018-01-01)

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer
by: Chow, L.Q.M, et al.
Published: (2022)

COMPARISON OF CHEMOTHERAPY RESPONSE AND ADVERSE EFFECTS OF DOUBLE-PLATINUM PLUS EGFR-TKI VERSUS DOUBLE-PLATINUM ALONE ON NSLCLC PATIENTS WITH DISEASE PROGRESSION AND EGFR-TKI TREATMENT
by: Laksmi Wulandari, et al.
Published: (2017-12-01)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
by: Xin Li, et al.
Published: (2020-03-01)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
by: Yang Wei, MD, et al.
Published: (2021-07-01)

Effects of BBB-permeable EGFR-TKI on neuropathic pain: Involvement of neuroinflammation
by: Wen-Chien Ho, et al.
Published: (2018)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)